314 related articles for article (PubMed ID: 27681434)
1. Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.
Sangaletti S; Tripodo C; Santangelo A; Castioni N; Portararo P; Gulino A; Botti L; Parenza M; Cappetti B; Orlandi R; Tagliabue E; Chiodoni C; Colombo MP
Cell Rep; 2016 Sep; 17(1):233-248. PubMed ID: 27681434
[TBL] [Abstract][Full Text] [Related]
2. SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities.
Sangaletti S; Talarico G; Chiodoni C; Cappetti B; Botti L; Portararo P; Gulino A; Consonni FM; Sica A; Randon G; Di Nicola M; Tripodo C; Colombo MP
Front Immunol; 2019; 10():1369. PubMed ID: 31281314
[TBL] [Abstract][Full Text] [Related]
3. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Zhao Q; Guo J; Wang G; Chu Y; Hu X
Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
[TBL] [Abstract][Full Text] [Related]
4. Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer.
Chiodoni C; Sangaletti S; Colombo MP
J Leukoc Biol; 2017 Aug; 102(2):287-292. PubMed ID: 28148719
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
6. Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer.
Chang CH; Yen MC; Liao SH; Hsu YL; Lai CS; Chang KP; Hsu YL
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28718842
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
8. SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.
Ma J; Ma Y; Chen S; Guo S; Hu J; Yue T; Zhang J; Zhu J; Wang P; Chen G; Liu Y
Biochem Biophys Res Commun; 2021 Jun; 558():134-140. PubMed ID: 33910127
[TBL] [Abstract][Full Text] [Related]
9. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells.
Song JH; Eum DY; Park SY; Jin YH; Shim JW; Park SJ; Kim MY; Park SJ; Heo K; Choi YJ
PLoS One; 2020; 15(10):e0240533. PubMed ID: 33091036
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
12. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
Puolakkainen PA; Brekken RA; Muneer S; Sage EH
Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
[TBL] [Abstract][Full Text] [Related]
13. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation.
Taki M; Abiko K; Baba T; Hamanishi J; Yamaguchi K; Murakami R; Yamanoi K; Horikawa N; Hosoe Y; Nakamura E; Sugiyama A; Mandai M; Konishi I; Matsumura N
Nat Commun; 2018 Apr; 9(1):1685. PubMed ID: 29703902
[TBL] [Abstract][Full Text] [Related]
14. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
15. Xuanhusuo powder has an anti-breast cancer effect by inhibiting myeloid-derived suppressor cell differentiation in the spleen of mice through down-regulating granulocyte colony stimulating factor.
Mao Y; Liu X; He K; Lin C; He B; Gao J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 52(1):88-100. PubMed ID: 37283122
[TBL] [Abstract][Full Text] [Related]
16. Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.
Güttlein LN; Benedetti LG; Fresno C; Spallanzani RG; Mansilla SF; Rotondaro C; Raffo Iraolagoitia XL; Salvatierra E; Bravo AI; Fernández EA; Gottifredi V; Zwirner NW; Llera AS; Podhajcer OL
Mol Cancer Res; 2017 Mar; 15(3):304-316. PubMed ID: 28031408
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
Cai J; Cui Y; Yang J; Wang S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
[TBL] [Abstract][Full Text] [Related]
18. Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.
Gupta N; Gaikwad S; Kaushik I; Wright SE; Markiewski MM; Srivastava SK
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068008
[TBL] [Abstract][Full Text] [Related]
19. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.
Triulzi T; Casalini P; Sandri M; Ratti M; Carcangiu ML; Colombo MP; Balsari A; Ménard S; Orlandi R; Tagliabue E
PLoS One; 2013; 8(2):e56761. PubMed ID: 23441215
[TBL] [Abstract][Full Text] [Related]
20. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.
Cao Y; Slaney CY; Bidwell BN; Parker BS; Johnstone CN; Rautela J; Eckhardt BL; Anderson RL
Cancer Res; 2014 Sep; 74(18):5091-102. PubMed ID: 25224959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
